Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

NCT02963935 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02963935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
February 6, 2017
Completion date
June 19, 2018
Enrollment
282 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metabolism and nutrition disorder, obesity